28489-44-3Relevant academic research and scientific papers
Novel aminopyrimidine EGFR inhibitor
-
Paragraph 0314-0320; 0912-0917, (2021/03/24)
The present invention provides a novel aminopyrimidine compound that is a selective inhibitor of the fourth generation EGFR (T790M/C797S mutation), a pharmaceutical composition containing the compound, a useful intermediate for preparing the compound, and
NOVEL COMPOUNDS
-
Paragraph 0155, (2015/03/16)
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.
NOVEL COMPOUNDS
-
Page/Page column 29, (2013/11/18)
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.
5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS
-
Page/Page column 98, (2010/06/20)
This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
